We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“When we take a new drug to clinical testing, we have to be careful in terms of what dose can be tolerated, so it usually starts with phase 1, which is essentially to determine the drugs safety and tolerability, how much can be given, what are the potential [adverse] effects and toxicities. From prior experiences with other cancer trials of these classes of drugs, there are some known toxicities which we are aware of, and it has to go through a slow process of gradual dose-escalation.”
“On behalf of our dedicated team, we extend our sincere gratitude to the patients, families, investigators, and clinical staff whose commitment drove the success of our Phase 1a LP-184 trial, establishing a robust safety profile with encouraging signals of activity at therapeutic doses. Leveraging our RADR AI platform, we are now positioning LP-184 for targeted phase 1b and phase 2 studies. Our goals are to position LP-184 to address critical unmet needs in triple-negative breast cancer, non–small cell lung cancer, and other DNA damage repair–deficient cancers, which can unlock significant value for patients and investors alike.”
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: